Board of directors

Education and professional experience: Thomas holds an MBA from the Stockholm School of Economics, Sweden. Approximately 25 years of experience in senior positions in banking, life science, and healthcare. CEO of Investor Growth Capital (renamed as Patricia Industries) over the period 2002–2012, a private equity company owned by Investor AB with a focus on long-term investments in technology, industry, and healthcare. Former board member in life science companies, such as Swedish Orphan International AB (Chairman) and Carmel Pharma AB.

Other current engagement: Member of the Board of Biotage AB, Boule Diagnostics AB, Immedica Pharma Holding AB, Mabtech Group Holding AB, Mabtech Holding AB, Surgical Science Sweden AB, Swedencare AB (publ), and Board member in affiliates to these companies and smaller family companies.

Shareholding in Sedana Medical: 1,666,464 shares via Tedsalus AB. Independent in relation to the company, its management, and the company´s major shareholders.

Education and professional experience: Claus holds an M.Sc. from Copenhagen Business School, Denmark, and an MBA in Strategy and Finance from the UCLA Anderson School of Management. He was CEO of Atos Medical from early 2014 through to the end of 2018. Atos Medical was sold by EQT to PAI Partners during his tenure in 2016. From 2006 to 2014, Claus held numerous senior leadership positions in Coloplast A/S, a Danish global consumable Medtech company, most recently as President - North America, Japan, and Australia. Before joining Coloplast, Claus spent 10 years within corporate strategy, mergers and acquisitions, and private equity across industries working for McKinsey & Company, Nordic Capital, and Mattel.

Other current engagement: Claus is currently Senior Advisor to KKR & Co. Inc. and Managing Director of Eden Invest LLC.

Shareholding in Sedana Medical: 0 shares. Independent in relation to the company, its management, and the company´s major shareholders.

Education and professional experience: Hilde Furberg has an M.Sc. in Chemistry from Oslo University, Norway. Hilde is an independent consultant and professional Board member. She has extensive leadership experience from her 35 years in sales, marketing, strategy, and management within Pharma/Biotech, from both small and large global companies. Hilde has worked operationally in companies such as Genzyme and Baxter, most recently as Senior Vice President EMEA Rare Diseases at Sanofi Genzyme. In addition, Hilde has experience from positions as Board member in BerGenBio, Probi, Pronova, Clavis, Algeta, Tappin, and CombiGene and as Chairman of the Board of directors in Blueprint Genetics.

Other current engagement: Industrial Advisor to Investinor, as well as Board member in PCI Biotech, Calliditas Therapeutics, OncoZenge, Bio-Me, and Herantis.

Shareholding in Sedana Medical: 1,500 shares. Independent in relation to the Company and its management and in relation to major shareholders.

Education and professional experience: Ola holds an upper secondary school qualification in engineering specialising in chemistry from Gothenburg Technical Upper Secondary School, Sweden. Ola has more than 25 years of experience in the pharmaceutical industry mainly in marketing, sales, and different management positions including 4 years in the US for Pharmacia in the 1980s and 1990s. Ola also has more than 20 years of experience in the Medtech industry as CEO of Louis Gibeck AB where he was responsible for the company´s listing on the OTC exchange in Stockholm and as Managing Director EMEA at Hudson RCI AB after its acquisition of Louis Gibeck AB. Ola was the founder of Sedana Medical in 2005 and served as CEO until 2011.

Other current engagement: Chairman of the Board of Eataway AB. Member of the Board of TransCutan AB and Board member in small family companies.

Shareholding in Sedana Medical: 4,462,098 shares privately and via Magiola Consulting AB. Independent in relation to the company, its management, and the company´s major shareholders.

Education and professional experience: Christoffer holds an M.Sc. from Chalmers University of Technology and a master´s degree in economics from the School of Business and Economics at the University of Gothenburg, Sweden. During the period 2012-2020 he was CFO of XVIVO Perfusion AB. During the period 2015–2017, he led XVIVO’s North American operations and resided in the United States. From 2001 to 2012, he held leading positions in finance and strategic management at Novartis and LG Electronics.

Other current engagement: CEO (since 2022) at XVIVO Perfusion AB.

Shareholding in Sedana Medical: 10,000 shares. Independent in relation to the company, its management, and the company´s major shareholders.

Education and professional experience: Eva holds a B.Sc. from the School of Economics in Gothenburg, Sweden. Over 20 years of experience in the pharmaceutical and Medtech industries, mainly in marketing and sales as well as corporate management. Formerly VP Commercial Operations, International Region at Phadia / ThermoFisher Scientific, as well Strategic Affairs Director at Johnson & Johnson Nordic AB, Medical Device and Strategic Development Manager at Pfizer AB.

Other current engagement: Vice President Marketing at Olink Proteomics AB, Member of the Board of Senzime AB since 2020, CEO and Chairman of the Board of her own company Movits Consulting AB and deputy member of the board of Finnson & Partners AB.

Shareholding in Sedana Medical: 12,800 shares. Independent in relation to the company, its management, and the company´s major shareholders.